Novonesis (Novozymes) B
NSISBC
Rank in Stocks
#1158
Established in January 2024 through the amalgamation of Novozymes A/S and Chr.... Established in January 2024 through the amalgamation of Novozymes A/S and Chr. Hansen, Novonesis now stands as a prominent global leader in biosolutions. The firm's activities encompass the worldwide development and commercialization of industrial enzymes, diverse microorganisms, and vital biopharmaceutical ingredients. Distinctively, its Class B shares are listed independently and actively traded on various European exchanges.
Share Price
$70.10
Last synced: 2026-10-21
Market Cap
$19.48B
Change (1 day)
-4.64%
Change (1 year)
10.57%
Country
DK
Trade Novonesis (Novozymes) B (NSISBC)
Category
Basic Materials
Revenue for Novonesis (Novozymes) B (NSISBC)
Revenue in Oct 2026 TTM: 0
According to Novonesis (Novozymes) B latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novonesis (Novozymes) B from 2026 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $35.45B | - |
GB
|
|
| - | - |
FR
|
|
| $24.41B | - |
US
|
|
| $16.84B | - |
US
|
|
| $12.60B | - |
US
|
